Blood marker may predict prostate cancer relapse after radiation
NCT ID NCT03017794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a protein in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels in 118 men before, during, and after treatment. The goal is to see if changes in CgA are linked to cancer recurrence, which could lead to better monitoring in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks